54 results
6-K
EX-99.1
BLU
Bellus Health Inc
29 Mar 23
Current report (foreign)
5:26pm
2a RELIEF trial, and seeks compensatory damages, pre-judgment and post-judgment interest, as well as attorneys’ fees, expert fees, and any other … as attorneys’ fees, expert fees, and any other reasonable costs and expenses. On November 16, 2021, Plaintiff stipulated to dismissal of all claims
6-K
EX-99.1
BLU
Bellus Health Inc
14 Nov 22
Condensed Consolidated Interim Financial Statements of
5:26pm
damages, pre-judgment and post-judgment interest, as well as attorneys’ fees, expert fees, and any other reasonable costs and expenses. On November 16
6-K
EX-99.2
BLU
Bellus Health Inc
14 Nov 22
Condensed Consolidated Interim Financial Statements of
5:26pm
RELIEF trial, and seeks compensatory damages, pre-judgment and post-judgment interest, as well as attorneys’ fees, expert fees, and any other reasonable
6-K
EX-99.1
BLU
Bellus Health Inc
16 Sep 22
Investor Presentation NASDAQ/TSX - BLU September 16 th , 2022
4:40pm
) CHEST 153 (1): 196 - 209. 2. Kuzniar et al. (2007) Mayo Clin. Proc. 82(1) 56 - 60. 3. Ryan NM, (2018) Expert Opin Pharmacother 19(7): 687 - 711. 4
6-K
EX-99.1
BLU
Bellus Health Inc
10 Aug 22
Condensed Consolidated Interim Financial Statements of
4:56pm
interest, as well as attorneys’ fees, expert fees, and any other reasonable costs and expenses. On November 16, 2021, Plaintiff stipulated to dismissal
6-K
EX-99.2
q8oz39p56n1mp9mjbjq
10 Aug 22
Condensed Consolidated Interim Financial Statements of
4:56pm
6-K
EX-99.1
agu0ca tcvxf7c9i5e7
11 May 22
Condensed Consolidated Interim Financial Statements of
5:05pm
6-K
EX-99.2
sybu4b4cz
11 May 22
Condensed Consolidated Interim Financial Statements of
5:05pm
6-K
EX-99.1
0bhgwk
5 Apr 22
Current report (foreign)
4:07pm
40-F
ccj8m6f
23 Feb 22
Annual report (Canada)
5:20pm
40-F
EX-99.2
esgws1295gy3l
23 Feb 22
Annual report (Canada)
5:20pm
40-F
EX-99.3
klpj7l49v
23 Feb 22
Annual report (Canada)
5:20pm
40-F
EX-99.1
wwz4iaacj83pvql1
23 Feb 22
Annual report (Canada)
5:20pm
6-K
EX-99.2
xxolq7r5aq 4cl9np
13 Dec 21
BELLUS Health Announces Positive Topline Results from its Phase 2b SOOTHE Trial of BLU-5937 for the Treatment of Refractory Chronic Cough
7:19am
6-K
EX-99.1
mlak4vk1gmq3 2g
10 Nov 21
Condensed Consolidated Interim Financial Statements of
4:42pm
6-K
EX-99.2
lqt m4hes
10 Nov 21
Condensed Consolidated Interim Financial Statements of
4:42pm
6-K
EX-99.1
eo3tbabhjeob
11 Aug 21
Condensed Consolidated Interim Financial Statements of
4:43pm
6-K
EX-99.2
y2op9 vbg
11 Aug 21
Condensed Consolidated Interim Financial Statements of
4:43pm
6-K
EX-99.1
rot64ui3ihrprx uy9d8
10 May 21
Condensed Consolidated Interim Financial Statements of
4:48pm
6-K
EX-99.2
yspjh y4ga
10 May 21
Condensed Consolidated Interim Financial Statements of
4:48pm